Clinical Oncology
Volume 19, Issue 4 , Pages 223-227, May 2007

Three-year Single Institution Audit on Transfusion Requirements in Oncology Patients

  • U. Dernedde

      Affiliations

    • Norfolk and Norwich University Hospital NHS Trust, Norwich NR4 7UZ, UK
    • Corresponding Author InformationAuthor for correspondence: U. Dernedde, Norfolk and Norwich University Hospital NHS Trust, Norwich NR4 7UZ, UK. Tel: +44-1603-286286
  • ,
  • R. Dernedde

      Affiliations

    • Im Weedengarten 2, 67271 Battenberg, Germany
  • ,
  • L. Shepstone

      Affiliations

    • University of East Anglia, Norwich NR4 7TJ, UK
  • ,
  • A. Barrett

      Affiliations

    • Norfolk and Norwich University Hospital NHS Trust, Norwich NR4 7UZ, UK

Received 8 November 2005; received in revised form 31 October 2006; accepted 14 November 2006.

Abstract 

Aims

To assess recent developments in the use of transfusions.

Materials and methods

Data from hospital-based sources were condensed in a single spread sheet covering 1611 transfusions of a total of 881 patients together with data on 25 264 treatment sessions in 6137 patients within a time period between 1 August 2001 and 31 July 2004.

Results

Our audit showed an increase in transfusions of 25% in 3 years. This was accompanied by an increased threshold for transfusions, as shown by a significant rise in mean haemoglobin trigger levels from 8.53 to 8.86g/dl (P<0.001) as well as an increase in treatment sessions and patient numbers — especially for chemotherapy or combinations of chemotherapy and radiotherapy. The highest transfusion rates and also the greatest increments occurred in patients with carcinoma of the ovary, lung and pancreas. Within these groups, treatment regimens as well as treatment lines were additional predictive factors.

Conclusions

This audit gives a detailed view on rising trends in transfusion requirements and, in light of anticipated restrictions on resources, it identifies high-risk areas, where the use of alternatives, such as erythropoietin, could be considered.

Key words: Blood transfusions, chemotherapy, erythropoietin, radiotherapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0936-6555(06)00425-0

doi:10.1016/j.clon.2006.11.011

Clinical Oncology
Volume 19, Issue 4 , Pages 223-227, May 2007